Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016

Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016
Published Jun 30, 2016
46 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016, provides in depth analysis on Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) targeted pipeline therapeutics.

The report provides comprehensive information on the Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) targeted therap

  
Source:
Document ID
GMDHC0200TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Overview71
Therapeutics Development84
  Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Stage of Development81
  Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Therapy Area91
  Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Indication102
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Companies142
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Therapeutics Assessment166
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action171
  Assessment by Route of Administration182
  Assessment by Molecule Type202
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Companies Involved in Therapeutics Development228
  Aeterna Zentaris Inc.221
  AGV Discovery, SAS231
  Asana BioSciences, LLC241
  Genentech, Inc.251
  Kura Oncology, Inc.261
  Laurent Pharmaceuticals Inc.271
  Merck &Co., Inc.281
  Merck KGaA291
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Drug Profiles3011
  ASN-007 Drug Profile301
  CB-745 Drug Profile311
  fenretinide Drug Profile321
  JRP-890 Drug Profile331
  KO-947 Drug Profile341
  RG-7842 Drug Profile351
  SCH-722984 Drug Profile361
  Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology Drug Profile371
  sprifermin Drug Profile382
  ulixertinib Drug Profile401
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Dormant Projects411
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Discontinued Products421
Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Featured News &Press Releases432
  Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting431
  Jun 15, 2015: Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis431
  May 20, 2014: Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis441
Appendix452
  Methodology451
  Coverage451
  Secondary Research451
  Primary Research451
  Expert Panel Validation451
  Contact Us451
  Disclaimer461

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mitogen-Activated-Protein-Kinase-1-MAP-Kinase-1-or-MAPK-1-or-Extracellular-Signal-Regulated-Kinase-2-or-ERK-2-or-Protein-Tyrosine-Kinase-ERK2-or-EC-2-7-11-24-Pipeline-Review-H1-2016-2088-16095>
  
APA:
Global Markets Direct - Market Research. (2016). Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mitogen-Activated-Protein-Kinase-1-MAP-Kinase-1-or-MAPK-1-or-Extracellular-Signal-Regulated-Kinase-2-or-ERK-2-or-Protein-Tyrosine-Kinase-ERK2-or-EC-2-7-11-24-Pipeline-Review-H1-2016-2088-16095>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.